Immunic, Inc. to Showcase Innovations at Upcoming September Conferences

Immunic, Inc. (Nasdaq: IMUX), a leading biotechnology company that focuses on the development of innovative small molecule therapies for chronic inflammatory and autoimmune diseases, is scheduled to participate in several important investor and scientific conferences in September 2025. These events will allow Immunic to present its groundbreaking research and ongoing clinical programs, particularly focusing on the promising drug candidate Vidofludimus Calcium (IMU-838).

Upcoming Conferences

H.C. Wainwright 27th Annual Global Investment Conference

From September 8 to 10, Immunic's President and Chief Operating Officer, Jason Tardio, will present an overview of the company's strategies and achievements at the H.C. Wainwright Annual Global Investment Conference. The on-demand presentation will be made available on September 5, 2025, starting at 7:00 AM ET through the H.C. Wainwright Conference Portal, along with the Events and Presentations section of the Immunic website. Alongside Mr. Tardio, Dr. Daniel Vitt, Chief Executive Officer, and Jessica Breu, Vice President of Investor Relations and Communications will be available for one-on-one investor meetings throughout the event in New York.

To schedule a meeting, interested parties can log on to www.hcwevents.com or reach out directly to Jessica Breu via email.

Leerink Partners Biopharma Summit

Following the H.C. Wainwright conference, Dr. Vitt will be attending the Leerink Partners Biopharma Summit from September 17 to 19 in Healdsburg, California. This summit will provide a platform to discuss advances in biopharmaceutical development.

41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

A significant highlight for Immunic will be their participation in the 41st ECTRIMS Congress, set to take place from September 24 to 26 in Barcelona, Spain. The conference is prominent in the scientific community and their teams will showcase critical data on Vidofludimus Calcium, specifically in the context of Multiple Sclerosis treatments.

Immunic's lead asset, Vidofludimus Calcium, has demonstrated not only neuroprotective effects as a first-in-class Nurr1 activator but also anti-inflammatory and anti-viral properties due to its role in inhibiting dihydroorotate dehydrogenase (DHODH). This dual functionality provides a strong foundation for its therapeutic use.

Oral Presentation and Late-breaking Posters

During this event, Dr. Robert J. Fox, a Staff Neurologist at the Cleveland Clinic, will present oral data from the Phase 2 CALLIPER trial, elaborating on the efficacy and safety of Vidofludimus Calcium in treating progressive forms of Multiple Sclerosis. This session is scheduled for September 24, 2025, from 2:35 PM to 2:45 PM CEST.

Additionally, Immunic will present late-breaking posters including findings on Vidofludimus Calcium's efficacy among primary progressive MS populations. The event will serve as an important platform to disseminate fresh data and foster discussions about the future implications of Immunic's research in combating chronic diseases. Members of Immunic's clinical and preclinical teams will be available throughout the conference and at booth #B37 for deeper engagement with the conference attendees.

About Immunic, Inc.

As a pioneering biotechnology firm, Immunic focuses on developing orally administered, small molecule therapies aimed at addressing chronic inflammatory and autoimmune diseases. Their flagship project, Vidofludimus Calcium, is currently in Phase 3 clinical trials for treating relapsing multiple sclerosis, with expected top-line data by the end of 2026. This innovative approach not only presents therapeutic opportunities but also caters to addressing critical patient needs in an evolving medical landscape. To learn more about Immunic’s mission and ongoing research programs, visit their website at www.imux.com.

Conclusion

Immunic, Inc.’s participation in these conferences signals an exciting period for the company, as they continue to engage with investors, share their findings with the scientific community, and ultimately strive to improve the lives of those affected by chronic inflammatory and autoimmune conditions.